PONTIAC

A RANDOMIZED PHASE II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TRASTUZUMAB DERUXTECAN VERSUS CDK4/6 INHIBITOR-BASED ENDOCRINE THERAPY AS FIRST-LINE THERAPY OF HR-POSITIVE AND HER2-LOW/ULTRALOW ADVANCED BREAST CANCER PATIENTS CLASSIFIED AS NON-LUMINAL SUBTYPE ACCORDING TO GENE EXPRESSION PROFILING. THE PRIMARY OBJECTIVE IS TO DEMONSTRATE THAT FIRST-LINE T-DXD COMPARED WITH CDK4/6i PLUS ENDOCRINE THERAPY IS SUPERIOR IN PROLONGING THE PROGRESSION FREE SURVIVAL IN PATIENTS WITH HR-POSITIVE, HER2-LOW ADVANCED BREAST CANCER CLASSIFIED AS NON-LUMINAL BY GENE EXPRESSION PROFILING.